{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:41:10Z","timestamp":1775580070699,"version":"3.50.1"},"reference-count":60,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL168045"],"award-info":[{"award-number":["R01HL168045"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA247648"],"award-info":[{"award-number":["U24CA247648"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OSU Comprehensive Cancer Center"},{"name":"Sylvan Frank Fellowship in Pharmaceutics"},{"name":"Eli Fellowship in Pharmaceutics"},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","award":["Pelotonia Fellowship Program"],"award-info":[{"award-number":["Pelotonia Fellowship Program"]}],"id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>TL-895 is an orally administered protein kinase inhibitor in clinical development for the treatment of B-cell malignancies and various other blood and autoimmune disorders. In the early stages of drug development, limited data are available to assess off-target engagement and drug\u2013drug interaction (DDI) liabilities, which may have profound effects on drug safety and efficacy. In this context, we characterized the kinase interaction profile of TL-895 and determined that the agent inhibits Bruton\u2019s tyrosine kinase (BTK) and bone marrow kinase on chromosome X (BMX), with more potent inhibition of BMX than BTK in a kinase assay (IC50: 0.53 vs. 3.02 nmol\/L) and a bioluminescence resonance energy transfer (BRET) assay (IC50: 1.6 vs. 6.8 nmol\/L). We used in vitro and in vivo models to assess DDI liabilities and identified TL-895 as a substrate of the hepatic uptake transporter OATP1B1 and the enzyme CYP3A4. In vivo, coadministration of TL-895 did not increase plasma concentrations of the endogenous and xenobiotic OATP1B1 substrates chenodeoxycholic acid 24-acyl-\u03b2-D-glucuronide, pravastatin, and gilteritinib, which indicates that TL-895 is an unlikely perpetrator of OATP1B1-mediated DDIs. Consistent with hepatic microsomal studies, we found that plasma concentrations of TL-895 were increased by 1.8- and 4.6-fold, respectively, in male and female mice lacking all CYP3A isoforms. The pharmacokinetic profile of TL-895 was not significantly sexually dimorphic or strain-dependent at drug doses producing human-equivalent measures of systemic exposure. These collective findings signify an important contribution of OATP1B1 and CYP3A4 to the in vivo handling of the dual BTK\/BMX inhibitor TL-895 and suggest the agent is an unlikely perpetrator of potentially deleterious DDIs in polypharmacy regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>TL-895 is an investigational second-generation BTK inhibitor for the treatment of B-cell malignancies. We found that TL-895 undergoes hepatocellular uptake by OATP1B-type transporters in advance of extensive CYP3A-mediated metabolism but is unlikely to perpetrate pharmacokinetic DDIs that could compromise drug safety in the context of polypharmacy regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0265","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:51:59Z","timestamp":1755877919000},"page":"1621-1630","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug\u2013Drug Interaction Liabilities with BTK Inhibitor TL-895"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-4617","authenticated-orcid":false,"given":"Jack C.","family":"Stromatt","sequence":"first","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-2630","authenticated-orcid":false,"given":"Eman A.","family":"Ahmed","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1361-8654","authenticated-orcid":false,"given":"Thomas","family":"Drabison","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-2699","authenticated-orcid":false,"given":"Mahesh R.","family":"Nepal","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6478-6907","authenticated-orcid":false,"given":"Anika T.","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1409","authenticated-orcid":false,"given":"Shelley J.","family":"Orwick","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-5711","authenticated-orcid":false,"given":"Daelynn R.","family":"Buelow","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-675X","authenticated-orcid":false,"given":"Eric D.","family":"Eisenmann","sequence":"additional","affiliation":[{"name":"2Division of Pharmaceutics and Pharmacology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6561-3295","authenticated-orcid":false,"given":"Kevin M.","family":"Huang","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-6644","authenticated-orcid":false,"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[{"name":"2Division of Pharmaceutics and Pharmacology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-3252","authenticated-orcid":false,"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[{"name":"2Division of Pharmaceutics and Pharmacology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"2025091203002341000_bib1","doi-asserted-by":"crossref","first-page":"20412","DOI":"10.1038\/s41598-023-47735-z","article-title":"Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies","volume":"13","author":"Goodstal","year":"2023","journal-title":"Sci Rep"},{"key":"2025091203002341000_bib2","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1080\/10428194.2021.1913139","article-title":"Phase I, first-in-human trial of Bruton\u2019s tyrosine kinase inhibitor M7583 in patients with B-cell malignancies","volume":"62","author":"Jurczak","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2025091203002341000_bib3","article-title":"Phase I\/II, FIH, dose escalation trial of TL-895 and expansion of TL-895 monotherapy and combination therapy with navtemadlin in tx-na\u00efve and R\/R CLL\/SLL subjects (NCT02825836)","author":"Telios Pharma Inc"},{"key":"2025091203002341000_bib4","volume-title":"Medicine NLo. Study of KRT-232 or TL-895 in Janus associated kinase inhibitor treatment-Na\u00efve myelofibrosis. 2021 - doi identifier: NCT04878003","author":"ClinicalTrials.gov","year":"2022"},{"key":"2025091203002341000_bib5","volume-title":"Study of KRT-232 or TL-895 in janus associated kinase inhibitor treatment-na\u00efve myelofibrosis (NCT04878003). Bethedsa (MD): ClinicalTrials.gov","author":"Telios Pharma Inc","year":"2022"},{"key":"2025091203002341000_bib6","article-title":"Study of TL-895 combined with Ruxolitinib in JAKi treatment-na\u00efve MF Subjects and subjects with MF who have a suboptimal response to ruxolitinib","volume-title":"NCT052805090. Bethedsa (MD): ClinicalTrials.gov","author":"Telios Pharma Inc","year":"2023"},{"key":"2025091203002341000_bib7","doi-asserted-by":"crossref","first-page":"e09624cd","DOI":"10.1097\/01.HS9.0000971048.09624.cd","article-title":"P1038: TL-895, a first-in-class, covalent bruton tyrosine kinase inhibitor (BTKi) for the treatment of myelofibrosis (MF) patients (pts) with severe thrombocytopenia (platelets (PLTS) &lt;50 K\/uL)","volume":"7","author":"Loschi","year":"2023","journal-title":"Hemasphere"},{"key":"2025091203002341000_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.clim.2016.01.012","article-title":"Btk inhibition treats TLR7\/IFN driven murine lupus","volume":"164","author":"Bender","year":"2016","journal-title":"Clin Immunol"},{"key":"2025091203002341000_bib9","first-page":"2013","article-title":"Imbruvica (Ibrutinib)","year":"2013"},{"key":"2025091203002341000_bib10","article-title":"Calquence (Acalabrutinib)","year":"2019"},{"key":"2025091203002341000_bib11","article-title":"Brukinsa (Zanubrutinib)","year":"2019"},{"key":"2025091203002341000_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025091203002341000_bib13","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025091203002341000_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2025091203002341000_bib15","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1182\/blood-2023-186517","article-title":"A phase (Ph) 2 study of TL-895, a highly selective, novel covalent BTK Inhibitor (BTKi), in patients (pts) with treatment-naive (TN) and relapsed\/refractory (R\/R) BTKi-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)","volume":"142","author":"Byrd","year":"2023","journal-title":"Blood"},{"key":"2025091203002341000_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrd3439","article-title":"Trial watch: phase II failures: 2008\u20132010","volume":"10","author":"Arrowsmith","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"2025091203002341000_bib17","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"key":"2025091203002341000_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/90761","article-title":"ADMET\u2013turning chemicals into drugs","volume":"19","author":"Hodgson","year":"2001","journal-title":"Nat Biotechnol"},{"key":"2025091203002341000_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd4609","article-title":"An analysis of the attrition of drug candidates from four major pharmaceutical companies","volume":"14","author":"Waring","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2025091203002341000_bib20","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1060028018765159","article-title":"Cost of prescription drug-related morbidity and mortality","volume":"52","author":"Watanabe","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2025091203002341000_bib21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bcp.12787","article-title":"Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults","volume":"81","author":"de Vries","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"2025091203002341000_bib22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/pharmaceutics12090856","article-title":"Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors","volume":"12","author":"Garrison","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib23","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1002\/jps.24113","article-title":"Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors","volume":"103","author":"Shao","year":"2014","journal-title":"J Pharm Sci"},{"key":"2025091203002341000_bib24","doi-asserted-by":"crossref","first-page":"e3056","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio Protoc"},{"key":"2025091203002341000_bib25","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1158\/1078-0432.CCR-12-0761","article-title":"Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel","volume":"18","author":"de Graan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025091203002341000_bib26","doi-asserted-by":"crossref","first-page":"F56","DOI":"10.1152\/ajprenal.00486.2012","article-title":"Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2","volume":"304","author":"Harper","year":"2013","journal-title":"Am J Physiol Ren Physiol"},{"key":"2025091203002341000_bib27","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.1073\/pnas.1424313112","article-title":"Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4\/6 and OCT2 functions","volume":"112","author":"Pabla","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091203002341000_bib28","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025091203002341000_bib29","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/pharmaceutics14040694","article-title":"Interaction of antifungal drugs with CYP3A- and OATP1B-mediated venetoclax elimination","volume":"14","author":"Eisenmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/bcp.12563","article-title":"Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment","volume":"79","author":"Waters","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025091203002341000_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10637-006-5269-2","article-title":"Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients","volume":"24","author":"Li","year":"2006","journal-title":"Invest New Drugs"},{"key":"2025091203002341000_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1124\/dmd.123.001466","article-title":"Vincristine disposition and neurotoxicity are unchanged in humanized CYP3A5 mice","volume":"52","author":"Li","year":"2024","journal-title":"Drug Metab Dispos"},{"key":"2025091203002341000_bib33","article-title":"Bioanalytical method validation guidance for industry","author":"U.S. Food and Drug Administration (FDA)","year":"2018"},{"key":"2025091203002341000_bib34","doi-asserted-by":"crossref","first-page":"123437","DOI":"10.1016\/j.jchromb.2022.123437","article-title":"Determination of the endogenous OATP1B biomarkers glycochenodeoxycholate-3-sulfate and chenodeoxycholate-24-glucuronide in human and mouse plasma by a validated UHPLC-MS\/MS method","volume":"1210","author":"Jin","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025091203002341000_bib35","doi-asserted-by":"crossref","first-page":"122882","DOI":"10.1016\/j.jchromb.2021.122882","article-title":"Development, validation, and application of an LC-MS\/MS method for the determination of the AXL\/FLT3 inhibitor gilteritinib in mouse plasma","volume":"1179","author":"Garrison","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025091203002341000_bib36","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/2767-9764.CRC-24-0332","article-title":"Systematic evaluation of tyrosine kinase inhibitors as OATP1B1 substrates using a competitive counterflow screen","volume":"4","author":"Drabison","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025091203002341000_bib37","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-21-0023","article-title":"Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation","volume":"27","author":"Hayden","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025091203002341000_bib38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/pharmaceutics15041149","article-title":"Pharmacokinetic boosting of kinase inhibitors","volume":"15","author":"Westra","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib39","doi-asserted-by":"crossref","first-page":"e13654","DOI":"10.1111\/nmo.13654","article-title":"Sexual dimorphism in upper gastrointestinal motility is dependent on duration of fast, time of day, age, and strain of mice","volume":"31","author":"Soni","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"2025091203002341000_bib40","first-page":"G171","article-title":"Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats","volume":"268","author":"Chen","year":"1995","journal-title":"Am J Physiol"},{"key":"2025091203002341000_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/pharmaceutics12040296","article-title":"Effect of food and an animal\u2019s sex on p-glycoprotein expression and luminal fluids in the gastrointestinal tract of Wistar rats","volume":"12","author":"Dou","year":"2020","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib42","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3390\/pharmaceutics14051030","article-title":"Sex differences in intestinal P-glycoprotein expression in Wistar versus Sprague Dawley rats","volume":"14","author":"Madla","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib43","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3390\/pharmaceutics14091933","article-title":"A metabolomics approach for predicting OATP1B-type transporter-mediated drug-drug interaction liabilities","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025091203002341000_bib44","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1124\/dmd.108.020594","article-title":"Utility of a novel Oatp1b2 knockout mouse model for evaluating the role of Oatp1b2 in the hepatic uptake of model compounds","volume":"36","author":"Chen","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2025091203002341000_bib45","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.3390\/molecules27206815","article-title":"Itraconazole-induced increases in gilteritinib exposure are mediated by CYP3A and OATP1B","volume":"27","author":"Garrison","year":"2022","journal-title":"Molecules"},{"key":"2025091203002341000_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1158\/2767-9764.CRC-21-0076","article-title":"Intentional modulation of ibrutinib pharmacokinetics through CYP3A inhibition","volume":"1","author":"Eisenmann","year":"2021","journal-title":"Cancer Res Commun"},{"key":"2025091203002341000_bib47","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/mol.112.084152","article-title":"Structure-based identification of OATP1B1\/3 inhibitors","volume":"83","author":"De Bruyn","year":"2013","journal-title":"Mol Pharmacol"},{"key":"2025091203002341000_bib48","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/molpharm.121.000287","article-title":"Influence of tyrosine kinase inhibition on organic anion transporting polypeptide 1B3-mediated uptake","volume":"101","author":"Hove","year":"2022","journal-title":"Mol Pharmacol"},{"key":"2025091203002341000_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/antiox11010076","article-title":"Adaptative up-regulation of PRX2 and PRX5 expression characterizes brain from a mouse model of chorea-acanthocytosis","volume":"11","author":"Federti","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"2025091203002341000_bib50","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1476-5381.2011.01724.x","article-title":"OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies","volume":"165","author":"Roth","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2025091203002341000_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tips.2011.10.005","article-title":"Functions of OATP1A and 1B transporters in vivo: insights from mouse models","volume":"33","author":"Iusuf","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"2025091203002341000_bib52","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/dmd.114.057976","article-title":"Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins","volume":"42","author":"Salphati","year":"2014","journal-title":"Drug Metab Disposition"},{"key":"2025091203002341000_bib53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1023\/A:1018877803319","article-title":"Interrelationship between substrates and inhibitors of human CYP3A and P-Glycoprotein","volume":"16","author":"Kim","year":"1999","journal-title":"Pharm Res"},{"key":"2025091203002341000_bib54","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejpb.2019.07.011","article-title":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices","volume":"142","author":"Pepin","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"2025091203002341000_bib55","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-16-0511","article-title":"The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance in ABCB1- and ABCC10-overexpressing cells and tumors","volume":"16","author":"Zhang","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2025091203002341000_bib56","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1021\/acs.molpharmaceut.8b00702","article-title":"P-Glycoprotein (MDR1\/ABCB1) restricts brain penetration of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib, while cytochrome P450-3A (CYP3A) limits its oral bioavailability","volume":"15","author":"van Hoppe","year":"2018","journal-title":"Mol Pharm"},{"key":"2025091203002341000_bib57","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cpt.2670","article-title":"Clinical relevance of hepatic and renal P-gp\/BCRP inhibition of drugs: an international transporter consortium perspective","volume":"112","author":"Taskar","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025091203002341000_bib58","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1182\/bloodadvances.2022007952","article-title":"BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors","volume":"6","author":"Buelow","year":"2022","journal-title":"Blood Adv"},{"key":"2025091203002341000_bib59","article-title":"TL-895 and KRT-232 study in acute myeloid leukemia","volume-title":"Bethedsa (MD)","author":"ClinicalTrials.gov. Medicine NLo","year":"2021"},{"key":"2025091203002341000_bib60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI91893","article-title":"Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia","volume":"128","author":"van Oosterwijk","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0265\/3644649\/crc-25-0265.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1621\/3650721\/crc-25-0265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1621\/3650721\/crc-25-0265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T07:00:35Z","timestamp":1757660435000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1621\/765116\/Drug-Drug-Interaction-Liabilities-with-BTK"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0265","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30111359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111371","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30111350","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8031194","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}